Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.K2M, a US-based spinal device company, has launched its new injectable polymer technology. Preliminary testing indicates the polymer may have many different applications for treating a variety of spinal disorders.
Subscribe to our email newsletter
K2M has obtained the worldwide exclusive rights for all spinal applications of this material through an agreement with Promethean Surgical Devices in November 2008.
In furtherance of K2M’s goal to be a market leader in the complex spine market, the injectable polymer will serve as a platform for the development of new implantable technologies.
The material has demonstrated unique properties that could lead to the development of a new treatment modality and earlier intervention to address multiple pathologies, such as spinal nucleus replacement, or micro-access surgical approaches for annular decompression and repair, the company said.
Eric Major, president and CEO of K2M, said: “K2M is excited to be a part of the rapidly expanding biomaterials sector of the spine industry that has the potential to radically improve surgery outcome by providing technologies for earlier patient intervention.
“The debut of this injectable polymer reaffirms K2M’s commitment to our new Biomaterials R&D division and demonstrates investment in our near and long term pipeline of differentiated technologies.”